Rib-X Teams With Sanofi To Develop Novel, Broad-Spectrum Antibiotics
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal enables biotech to monetize a portion of its ribosome research while maintaining control over larger segments.
You may also be interested in...
Re-Named Melinta Moving Ahead With Delafloxacin And Novel Class Of Antibiotics
Formerly known as Rib-X Pharmaceuticals, Connecticut biotech reacquires rights to RX-04 antibiotic platform from Sanofi and moves forward with venture backing from Vatera and new management team.
Without an IPO, Rib-X Raises $67.5 Million In Venture Funding
Rib-X will use the venture infusion to try to replicate Phase IIb data that indicated superiority to vancomycin for its broad-spectrum fluoroquinolone antibiotic.
Antibiotic Legislation Offers Big GAIN For Small Firm: Rib-X Extends Delafloxacin Exclusivity
Rib-X is among the first to take advantage of the Generating Antibiotic Incentives Now provisions of the FDA reauthorization legislation with five years’ extra exclusivity for its lead broad spectrum antibiotic candidate, a next-generation fluoroquinolone. Designation for the program came swiftly, company says.